Alenvir 25 mg (Tablet)

Indications

• Treatment of chronic hepatitis B virus infection in adults with compensated liver disease

Pharmacology

• Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor
• Enters primary hepatocytes by passive diffusion
• Converted to tenofovir through hydrolysis in primary hepatocytes
• Phosphorylated to tenofovir diphosphate, which inhibits HBV replication

Dosage & Administration

• Recommended dosage of 25 mg (one tablet) taken orally once daily with food in adults
• No dosage adjustment in patients with estimated creatinine clearance greater than or equal to 15 ml per minute
• Not recommended in patients with decompensated hepatic impairment

Interaction

• Is a substrate of P-glycoprotein and BCRP
• Drugs that strongly affect P-gp and BCRP activity may lead to changes in absorption
• Coadministration with drugs that inhibit P-gp and BCRP may increase plasma concentration

Side Effects

• Most common side effects include headache, stomach pain, tiredness, cough, nausea, back pain

Pregnancy & Lactation

• Prevalence of birth defects in live births following exposure to TAF-containing regimens
• Tenofovir alafenamide presence and effects on breastfed infant unknown

Precautions & Warnings

• Discontinuation may result in severe acute exacerbations of hepatitis B
• Not recommended for treatment of HIV-1 infection
• Postmarketing cases of renal impairment reported with TAF-containing products
• Lactic acidosis and severe hepatomegaly with steatosis reported with nucleoside analogs

Overdose Effects

• Monitor patient for evidence of toxicity
• Efficiently removed by hemodialysis

Therapeutic Class

• Hepatic viral infections (Hepatitis B)

Storage Conditions

• Store below 30°C
• Keep in original container
• Protect from light
• Keep out of children’s reach

Related Brands

• Alfavir 25 mg (Tablet) - incepta-pharmaceuticals-ltd
• Nexataf 25 mg (Tablet) - everest-pharmaceuticals-ltd